Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6832639 | 1.00 | MEN1 (0.49) | MEN1KMT2AFGFR1RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL6835840 | 0.99 | MEN1 (0.48) | MEN1KMT2AFGFR1RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL6835843 | 0.99 | MEN1 (0.48) | MEN1KMT2AFGFR1RAB9ANPC1 | |
| SCHEMBL6835941 | 0.87 | ALDH1A1 (0.56) | KMT2ARAB9ANPC1POLB | |
| SCHEMBL6835939 | 0.87 | ALDH1A1 (0.56) | KMT2ARAB9ANPC1POLB | |
| SCHEMBL6583981 | 0.85 | MEN1 (0.58) | MEN1KMT2AFGFR1RAB9ANPC1 | |
| SCHEMBL6583988 | 0.85 | MEN1 (0.58) | MEN1KMT2AFGFR1RAB9ANPC1 | |
| SCHEMBL7473227 | 0.82 | RAB9A (0.42) | MEN1KMT2ARAB9ANPC1POLB | |
| SCHEMBL6835921 | 0.82 | TP53 (0.42) | MEN1KMT2ARAB9ANPC1POLB | |
| SCHEMBL7473215 | 0.82 | RAB9A (0.42) | MEN1KMT2ARAB9ANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040181062-A1 | Benzimidazole cyclooxygenase-2 inhibitor | PFIZER INC | 2004-09-16 | — | — | US | disclosed |
| US-6713482-B2 | SUCH AS (E)-1-(2-PYRIDYL)-2-STYRYL-1H-BENZIMIDAZOLE; ANTIINFLAMMATORY AND ANALGESIC AGENTS; PROSTAGLANDIN INHIBITORS | PFIZER INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030013886-A1 | Benzimidazole cyclooxygenase-2 inhibitors | OKUMURA YOSHIYUKI (JP) | 2003-01-16 | — | — | US | disclosed |
| EP-0937722-B1 | Benzimidazole derivatives as cyclooxygenase-2 inhibitors | PFIZER (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6310079-B1 | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | PFIZER INC. | 2001-10-30 | — | — | US | disclosed |
| EP-0937722-A1 | Benzimidazole derivatives as cyclooxygenase-2 inhibitors | PFIZER INC. (US) | 1999-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013886-A1 | Benzimidazole cyclooxygenase-2 inhibitors | PTGS1, CBR1, CBR3 | MEN1 4840/4885KMT2A 1611/4885FGFR1 3309/4885 |
| US-20040181062-A1 | Benzimidazole cyclooxygenase-2 inhibitor | PTGS1, CBR1, CBR3 | MEN1 4821/4885KMT2A 1403/4885FGFR1 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.